Arginine promotes angio-osteogenesis by attenuating oxidative stress-induced bone loss and ameliorating mitophagy

Yang Shen  
Sir Run Run Shaw Hospital

Haoming Wang  
Sir Run Run Shaw Hospital

Hongwei Xie  
Sir Run Run Shaw Hospital

Qingliang Ma  
Sir Run Run Shaw Hospital

Shiyu Wang  
Sir Run Run Shaw Hospital

Putao Yuan  
Sir Run Run Shaw Hospital

Hong Xue  
Sir Run Run Shaw Hospital

Huaxing Hong  
Taizhou Hospital of Zhejiang Province, Wenzhou Medical University

Shunwu Fan  
Sir Run Run Shaw Hospital

Wenbin Xu  
Sir Run Run Shaw Hospital

Ziang Xie  
ziang_xie@zju.edu.cn  
Sir Run Run Shaw Hospital

Research Article

Keywords: angiogenesis, arginine, mitophagy, osteogenesis

Posted Date: September 7th, 2023

DOI: https://doi.org/10.21203/rs.3.rs-3322055/v1
Abstract

Osteoporosis is one of the most common bone diseases in middle-aged and elderly populations worldwide. Development of new drugs to treat the disease is a key focus of research. Current treatments for osteoporosis mainly directed at promoting osteoblasts and inhibiting osteoclasts. However, there is currently no ideal approach for osteoporosis treatment. Arginine is a semi-essential amino acid that is involved in numerous biological processes. Several studies have demonstrated its effects on NO production, protein biosynthesis, and immune responses. In this study, the specific effect of arginine on osteoporosis was explored. We found that arginine attenuates bone loss in aged mice. Indeed, arginine was found to promote osteogenesis and angiogenesis in these animals. Moreover, we showed that arginine can increase the activity of vascular endothelial cells and promote osteogenesis, whereas it inhibited adipogenesis in vitro. In addition, we found an effect of arginine on mitochondria in osteoblast-lineage and endothelial cells. Specifically, arginine altered the expression of PINK1/Parkin or Bnip3 in mitochondria of these cells, thereby promoting mitophagy, and protecting cells from ROS. Similarly, arginine treatment effectively ameliorated osteoporosis in an ovariectomized mouse model. In conclusion, arginine supplementation might be an effective therapy in the treatment of osteoporosis.

Introduction

Bone remodeling is critical for bone homeostasis. Once skeletal cells are inhibited or abnormally active, this balance is disrupted, leading to osteoporosis (Rodan et al., 2020). The incidence of osteoporosis, an age-related systemic skeletal disorder, has remained high among the elderly population in recent years. One in three women and one in five men are at risk of bone fractures caused by osteoporosis (Greenwood et al., 2018). Further, increased bone fragility and susceptibility to fractures greatly reduce the quality of life of these patients (Compston et al., 2019). Efficient therapies are currently available for osteoporosis. Antiresorptive therapies, including denosumab and bisphosphonates, and anabolic medications, including parathyroid hormone, have been used clinically to reduce bone resorption or stimulate bone formation. However, besides the therapeutic effects, these drugs have side effects that cannot be ignored. Therefore, natural biological agents that can promote angio-osteogenesis and attenuate osteoclastogenesis with fewer side effects are required to treat osteoporosis (Reid and Billington, 2022; Khosla and Hofbauer, 2017).

Autophagy refers to the process through which parts of the cell are degraded in the lysosome; it plays an irreplaceable role in the homeostasis of cells, tissues, and organs. Many autophagy-related genes have clear etiological correlations with human diseases (Mizushima and Levine, 2020; Levine and Kroemer, 2019). Autophagy not only maintains intracellular nutrition through the degradation of intracellular components but also selectively eliminates organelles to maintain the organellar balance in terms of quantity and quality. Bone homeostasis is also closely related to autophagy, which can modulate this process by affecting osteoblasts, osteoclasts, osteocytes, and other bone tissues (Guo et al., 2021). Mitophagy is a specific type of autophagy that targets damaged mitochondria (Bravo-San Pedro et al., 2017). When mitochondria are damaged, continuous depolarization occurs in the inner membrane, which
stabilizes phosphatase and tensin homolog deleted on chromosome ten (PTEN)-induced kinase 1 (PINK1), resulting in the recruitment of Parkin to the outer mitochondrial membrane. Parkin ubiquitinates proteins and recruits mitochondria to the autophagic pathway (Youle and Narendra, 2011; Kerr et al., 2017). The PINK1/Parkin-related pathway is the primary mitophagic pathway, especially in Parkinson’s disease. Several studies have demonstrated that BCL2 and adenovirus E1B 19 kDa-interacting protein3 (Bnip3) play a significant role in mitophagy (Jin et al., 2018; Li et al., 2018). Moreover, recent studies have shown that mitochondrial reactive oxygen species (ROS) level is limited by Bnip3-associated mitochondrial autophagy and that a relationship exists between mitochondrial ROS production and Bnip3 expression (Zhang et al., 2009).

As a semi-essential amino acid, arginine participates in various key physiological and biochemical activities in the human body. It is a component of the body's defense against pathogen invasion and is used as a dietary supplement to promote muscle strength recovery (Alvares et al., 2012; Gogoi et al., 2016). Arginine is a key substrate for the synthesis of NO and can be converted to urea and L-ornithine through the action of arginase. In adults, arginine is used to produce citrulline and ornithine in quantities sufficient to meet the requirements of the urea cycle. However, arginine may become conditionally essential in some situations. For example, in neonates and children, the amount of arginine produced in the body during development is insufficient for growth, whereas, in the elderly population, endogenous arginine synthesis is lacking. Previous studies have shown that arginine supplementation promotes thymic regrowth and reactivation of thymic function in aged animals (Mocchegiani et al., 2006). In addition, we previously found that mechanical force can regulate asymmetric dimethylarginine production by affecting the expression of the hydrolase dimethylarginine dimethylamine hydrolase 1 in osteoblasts (Xie et al., 2022), suggesting that arginine-derived compounds might play a regulatory role in bone homeostasis. However, the association between mitophagy and arginine has not been fully elucidated in previous bone-remodeling studies. Accordingly, the aim of our study was to investigate whether arginine can alleviate osteoporosis, explore whether it can alter cell differentiation through its effect on mitochondria, and determine whether it can be used as an adjunct supplement therapy in the treatment of osteoporosis.

Methods

Chemicals and reagents

Arginine was obtained from Solarbio (A0013, Beijing, China). S-(2-Boronethyl)-L-Cysteine hydrochloride (BEC-HCl) was obtained from Selleck (Shanghai, China, S7929). Fetal bovine serum (FBS) and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Gibco (Carlsbad, USA). Minimal essential medium (MEM) was from Procell (Wuhan, China). Antibodies against BNIP3 and Runt-related transcription factor 2 (RUNX2) were purchased from Abcam (Cambridge, USA). Antibodies against PINK1, Parkin, peroxisome proliferator-activated receptors γ (PPARγ), fatty acid binding protein 4 (FABP4), and CCAAT/enhancer binding protein γ (CEBPγ) were purchased from Proteintech (Wuhan, China). Cell Counting Kit-8 was purchased from Dojindo Molecular Technology (Kumamoto, Japan).
**Osteogenic differentiation assay**

Osteoblasts were isolated from the cranial cap bone of C57BL/6 mice (3-d postnatal), as previously reported (Chen et al., 2015). Isolated osteoblasts were cultured in DMEM in a conditioned incubator. Osteoblasts were seeded in 24-well plates with DMEM-based osteogenic induction medium (10% FBS, 50 mM L-ascorbic acid 2-phosphate, and 10 mM β-glycerophosphate). An alkaline phosphatase (ALP) staining kit (CWBio, Beijing) was used for osteoblast staining at 7 d. Alizarin red solution (ARS; Cyagen Biosciences, Guangzhou, China) was used for osteoblasts at 21 d.

**Adipogenic differentiation assay**

C3h10 cells were cultured in MEM in a conditioned incubator. Cells were seeded in 24-well plates with MEM-based adipogenic induction medium (10% FBS, 0.5 mM isobutylmethylxanthine, 0.25 µM dexamethasone, and 1 µg/mL insulin). The degree of adipogenic differentiation of cells was assessed using an Oil red O staining kit (Jiancheng, Nanjing, China).

**Cell migration and invasion assays**

Cell invasion assays were performed in 24-well transwell chambers (Corning, Tewksbury, USA). Human umbilical vein endothelial cells (HUVECs) were seeded inside transwell inserts with 200 µL of specific medium. Then, 600 µL of the medium was placed into the lower chamber. HUVECs located at the lower surface of the filters were fixed, stained with 0.1% crystal violet solution, and counted under a light microscope.

**Tube forming assay**

After the specific treatment protocol, HUVECs were seeded in 96-well plates with Matrigel (Corning) and incubated in a conditioned incubator. Cells were observed continuously for 2 h under a light microscope.

**Wound-healing assay**

HUVECs were seeded in six-well plates and scratched with a 200 µL pipette tip when the cell density reached approximately 80%. Images of the wounds from the same position were captured at 0 and 12 h post-injury. ImageJ software (National Institutes of Health; Bethesda, USA) was used to quantify the ratio of the initial wound area to the wound area remaining at 12 h.

**RNA extraction assay**

Total RNA was extracted using the Ultrapure RNA Kit (CWBio, Beijing). Complementary DNA (cDNA) was synthesized with a 10 µL system containing RNase-free water, 5×PrimeScript RT Master Mix (Takara Bio, Otsu, Japan), and total RNA. Then, cDNA was mixed with SYBR Green Master Mix (Yeason, Beijing, China), and RT-PCR experiments were performed using an ABI Prism 7500 system (Applied Biosystems, USA). The reaction parameters were stated as previously reported (Xie et al., 2018). Primer sequences
used for real-time RT-PCR are shown in Table S1. β-Actin expression was performed to normalize the expression of target genes. Results were analyzed using the ∆∆Ct method.

Western blot analysis

After cell treatments, the cells were lysed with RIPA lysis buffer, and total protein was extracted. Proteins were separated via 8 or 10% SDS-PAGE and transferred onto polyvinylidene fluoride membranes. Membranes were incubated in 5% FBS buffer for 60 min at room temperature and then incubated overnight with specific primary antibodies at 4 °C. The next day, membranes were incubated with secondary antibodies for 60 min at room temperature. Target bands were visualized using LAS-4000 Science Imaging System (Fujifilm, Tokyo, Japan).

Flow cytometry

HUVECs, osteoblasts, and C3H10 cells were seeded in six-well plates and treated as required. Mitochondrial membrane potential was evaluated using a JC-1 kit (C2003S; Beyotime, Shanghai, China). Samples were analyzed using an Accuri C6 flow cytometer (BD Biosciences, San Diego, USA).

Immunofluorescence staining

Cells were fixed and permeabilized with 0.5% Triton X-100. After incubation in 5% bovine serum albumin buffer, the samples were incubated with primary antibodies overnight and then incubated with the secondary antibody for 60 min, washed with phosphate-buffered saline (PBS), and stained with 4′,6-diamidino-2-phenylindole (DAPI; Beyotime). For mitochondrial staining, osteoblasts, HUVECs, or C3h10 cells were transfected with LC3 adenovirus, treated with MitoTracker (Beyotime), and fixed with 4% paraformaldehyde.

Mouse model and calcein dual fluorescent labeling

Animal experiments in our work were performed according to the NIH Guide for the Care and Use of Laboratory Animals and the guidelines for animal treatment of Sir Run Run Shaw Hospital (Hangzhou, China). Ten C57BL/6 mice (female mice, 12 months old) were randomly assigned to vehicle and arginine groups. Mice in the arginine group were given water containing dissolved arginine for two months and euthanized (Wei et al., 2022). For the ovariectomized (OVX) mouse model, 20 C57BL/6 mice (female, 12 weeks old) were randomly assigned to four groups (sham, vehicle, parathyroid hormone (PTH), and arginine), with five mice per group. The sham group was subjected to a sham operation, whereas the vehicle, PTH, and arginine groups were subjected to ovariectomy. Four weeks later, mice were i.p. injected with PBS (sham and vehicle group), 10 µg/kg PTH (PTH group), or 80 mg/kg L-arginine (arginine group) twice per week for 6 weeks. All mice were i.p. injected with calcein at 10 and 3 d before being euthanized. Femurs were separated and fixed in 4% paraformaldehyde for immunofluorescence and micro-computed tomography (µCT).

µCT scanning
Mouse femurs were scanned with a Micro CT instrument (Skyscan, Antwerp, Belgium). Trabecular bone volume per total volume (BV/TV), mean trabecular separation (Tb.Sp), mean trabecular number (Tb.N), mean trabecular thickness (Tb.Th), and bone mineral density (BMD) were measured as previously reported (Ma et al., 2022).

**Statistical analysis**

The data was analyzed by GraphPad Prism (GraphPad Software, Boston, USA). Statistical differences were determined using a one-way ANOVA followed by Tukey’s post hoc analysis or Student’s t test. Differences were considered significant at \( p < 0.05 \) (two-tailed test).

**Results**

**Arginine prevents bone loss in mildly aged mice**

First, we investigated whether arginine could affect bone mass changes when fed to 12-month-old elder female mice. After two months of arginine supplementation, μCT demonstrated more bone mass in the arginine group than in the vehicle group (Figure 1A). Quantitative analysis revealed that the BV/TV, Tb.Th, Tb.N, cortical thickness (Cor.Th), and BMD were significantly increased, whereas Tb.Sp was markedly decreased in the arginine group (Figure 1B). Masson’s trichrome staining indicated more active osteoblasts in the arginine group than in the vehicle group (Figure 1C). Hematoxylin and eosin (H&E), von Kossa, and osteocalcin (OCN) staining also demonstrated the enhancement of bone formation in the arginine group (Figure 1D,E). Notably, we observed significantly lower perilipin expression in the arginine group than in the vehicle group (Figure 1D,E), which suggested that arginine led to less adipogenesis. Calcein dual fluorescent labeling demonstrated that arginine increased the mineral apposition rate (MAR) and bone formation rate per unit of the bone surface of the femur (Figure 1F,G). Considering the close association between osteogenesis and angiogenesis, we performed immunofluorescence staining for the vascular marker CD31/EMCN, which indicated that arginine significantly promoted angiogenesis in vivo (Figure 1H). Collectively, these results suggest that arginine prevents bone loss in elder mice by promoting osteogenesis and angiogenesis and inhibiting adipogenesis.

**Arginine promotes osteogenesis but inhibits adipogenesis in vitro**

To further investigate the effect of arginine on osteogenesis, we treated osteoblasts with different concentrations of arginine. These concentrations had no effect on cell activity (Figure S1A,B). ALP and ARS assays revealed that arginine promoted osteogenesis in a concentration-dependent manner (Figure 2A, Figure S1C). In addition, western blotting results showed that the expression of osteoblast-specific proteins, including osteopontin (OPN), RUNX2, and ALP, increased after arginine treatment (Figure 2B,C). Meanwhile, the expression levels of Runx2, Opn, and Sp7 increased (Figure 2D). Given the in vivo results, we investigated the effect of arginine on adipogenesis in C3h10 cells. Fewer adipocytes were observed after arginine treatment (Figure 2E, Figure S1D). Further, the protein expression of PPAR-γ and FABP4 was decreased (Figure 2F,G), as was the mRNA expression of Ppar-γ, Fabp4, and Klf5 (Figure 2H). However, we
did not observe significant effects of arginine on osteoclasts (Figure S1E). In conclusion, our data demonstrate that arginine promotes osteogenesis and inhibits adipogenesis.

**Arginine promotes angiogenesis in a concentration-dependent manner *in vitro***

We investigated the role of arginine in angiogenesis *in vitro* using HUVECs. After determining the appropriate concentration of arginine (Figure S2A), we found that arginine promoted the tube-forming ability of HUVECs, and an increased number of nodes and junctions were observed after arginine treatment (Figure 3A,B). Specifically, wound healing (Figure 3C,D) and cell migration experiments (Figure 3E,F) demonstrated positive results after treatment with arginine. Notably, the promoting effect of arginine on these parameters was the most significant when the treatment concentration was 200 μM. BEC-HCl is a competitive arginase II inhibitor (Colleluori and Ash, 2001). Interestingly, BEC-HCl treatment decreased the tube-forming ability of HUVECs (Figure S2B,C,D) and cell migration (Figure S2E,F). Collectively, arginine promotes angiogenesis in HUVECs *in vitro*, whereas BEC-HCl inhibits this process.

**Arginine rescues endothelial and osteoblast-lineage cells from ROS by affecting mitophagy***

We further investigated whether arginine could promote angiogenesis by affecting the mitochondria. For this, we treated HUVECs with H$_2$O$_2$. H$_2$O$_2$ induced the production of ROS, which can interact with cellular proteins, nucleic acids, and lipids to induce oxidative stress and disrupt the balance between oxidation- and reduction-regulated cellular processes, ultimately causing oxidative damage. After H$_2$O$_2$ treatment, abnormal mitochondrial morphology was observed. Mitochondria displayed an increase in fragment structure staining based on MitoTracker, and co-localization with LC3 staining showed that arginine promoted mitophagy (Figure 4A). We also investigated the expression of mitophagic genes, including Pink1, Parkin, and Bnip3. The mRNA expression of these genes increased after arginine treatment, with and without H$_2$O$_2$ treatment (Figure 4B). The protein expression of PINK1 and Parkin showed the same trend, whereas an increase in BINP3 was observed in arginine-treated cells exposed to H$_2$O$_2$-induced ROS (Figure 4C,D). As shown in Figure 4, H$_2$O$_2$ promoted the accumulation of JC-1 monomers in the mitochondria, indicating low membrane potential, whereas arginine rescued this phenotype (Figure 4E,F). To further validate its effects on mitochondria, we treated HUVECs with arginine and examined them using transmission electron microscopy (TEM). After H$_2$O$_2$ treatment, mitochondria were severely damaged and appeared to be vacuolated, which was reversed by arginine treatment (Figure 4G). Notably, BEC-HCl treatment downregulated the expression of PINK1, Parkin, and BNIP3 (Figure S3A,B). We also observed a decrease in the membrane potential of mitochondria (Figure S3C,D). Interestingly, the TEM images demonstrated vacuolated mitochondria after BEC-HCl treatment (Figure S3E). These results prove that arginine promotes angiogenesis and rescues cells from the effects of H$_2$O$_2$-induced ROS by affecting mitochondria and possibly changing the level of mitophagy.

Next, we investigated whether arginine could still influence osteoblasts or adipocytes when they were threatened by oxidative stress. The ALP and ARS assays revealed that H$_2$O$_2$ decreased the activity of osteoblasts, whereas arginine reversed this effect (Figure 5A,B). Arginine also rescued the reduction in
mitochondrial membrane potential caused by \( \text{H}_2\text{O}_2 \) (Figure 5C,D). In addition, we observed damaged mitochondria in \( \text{H}_2\text{O}_2 \)-treated osteoblasts using LC3-MitoTracker mitochondrial co-localization staining (Figure 5E). We found that the co-localization of MitoTracker and LC3 was reduced after BEC-HCl treatment (Figure S4A). Western blotting results also showed that arginine could rescue the decrease in BNIP3 protein expression induced by \( \text{H}_2\text{O}_2 \) at an early stage, whereas the expression of osteogenesis-related proteins, such as RUNX2 and OPN, was rescued at a late stage (Figure 5F,G). TEM confirmed the results of the mitochondrial staining (Figure 5H). Next, we performed the same experiments using adipocytes. Arginine reduced adipocyte formation following \( \text{H}_2\text{O}_2 \) treatment (Figure 6A). Moreover, flow cytometric analysis after JC-1 treatment demonstrated that arginine could effectively alleviate the decrease in mitochondrial membrane potential caused by \( \text{H}_2\text{O}_2 \) treatment (Figure 6B,C). LC3-MitoTracker mitochondrial co-localization staining indicated low membrane potential and rescue of this phenotype by arginine (Figure 6D). Conversely, decreased co-localization was observed in C3h10 cells after BEC-HCl treatment (Figure S4B). In addition, we observed the upregulation of Bnip3 expression after arginine treatment. The upregulation of FABP4 expression was observed in C3H10 cells after \( \text{H}_2\text{O}_2 \) treatment, whereas FABP4 expression was significantly reduced by the simultaneous addition of arginine. However, no significant alterations were observed in CEBP\( \alpha \) and PPAR\( \gamma \) levels (Figure 6E,F ). TEM revealed similar results of C3h10 cells with osteoblasts (Figure 6G). These results show that arginine protects cells from \( \text{H}_2\text{O}_2 \)-induced ROS by affecting the mitochondria and possibly changing the level of mitophagy.

**Arginine attenuates bone loss in OVX mice by promoting angio-osteogenesis**

Based on our findings, we were interested in whether arginine could exert a protective effect against ovariectomy-induced osteoporosis in mice. Compared to the sham group, the vehicle group showed significant bone loss based on \( \mu \)CT, which was prevented by PTH or arginine treatment (Figure 7A). Quantitative analysis revealed that BT/TV, Tb.N, Tb.Th, and Cor.Th were significantly decreased, and Tp.Sp was increased in the OVX-vehicle group, whereas these changes were reversed by PTH or arginine, except for Tp.Sp (Figure 7B,C). Dual fluorescent labeling with calcein demonstrated that arginine could increase the MAR of the femur in OVX mice (Figure 7D,E). Moreover, H&E staining demonstrated a decrease in trabecular bone in the vehicle group, whereas PTH or arginine treatment improved this. This result was confirmed through von Kossa and Masson's trichrome staining of femurs (Figure 7F). Meanwhile, expression of the osteogenesis-related gene **OCN** was decreased in the vehicle group compared with that in the sham group, whereas arginine or PTH reversed this effect (Figure 8A,B). In addition, the upregulation of perilipin expression in the vehicle group was suppressed in the arginine and PTH groups (Figure 8C,D). **In situ** staining for CD31/EMCN demonstrated a decrease in vessel formation in the vehicle group, which was improved by arginine or PTH (Figure 8E). Taken together, arginine attenuates OVX-induced osteoporosis, showing possible therapeutic potential.

**Discussion**
Osteoporosis is a serious disease that affects middle-aged and elderly individuals worldwide, especially postmenopausal women. With aging, bone homeostasis becomes disordered, the activity of osteoblasts decreases, osteoclasts become abnormally active, osteoporosis occurs, and the risk of fracture increases significantly. Currently, most drugs used for osteoporosis treatment, such as denosumab and bisphosphonates, target osteoclasts, inhibiting their activity and reducing bone resorption, thereby delaying the progression of osteoporosis (5). In this study, we found that the semi-essential amino acid arginine could promote osteogenesis while acting on other cells in the bone microenvironment to counteract the effect of oxidative stress on bone homeostasis. Additionally, we found that this process might occur through mitophagy mediated by the Bnip3 or PINK1/Parkin pathways, indicating that mitophagy could play a key role in the maintenance of bone homeostasis.

Angiogenesis and bone formation are inextricably linked. Within bone tissue, angiogenesis is regulated by signaling factors secreted by various cells in bones and blood vessels, which influence the formation of new bones (Kusumbe et al., 2014). Furthermore, changes in the skeletal microvasculature can influence abnormal bone formation in patients with osteoporosis (Burkhardt et al., 1987). Previous studies have shown that during fracture repair, osteoblasts secrete vascular endothelial growth factor A that promotes macrophage recruitment and angiogenesis, initiating the repair process (Tuckermann and Adams, 2021). Osteogenic precursor cells also co-invade vascular endothelial cells during fractured cartilage repair and promote healing (Maes et al., 2010). Type H vessels were recently found to be located near the metaphyseal growth plate, which exhibits a high expression of endomucin and CD31. Type H vessels produce specific factors, stimulate the proliferation and differentiation of bone marrow cells, and promote bone formation. Aged or OVX mice demonstrated a decrease in type H vessels, and this decrease was also observed in humans with aging (Kusumbe et al., 2014; Ramasamy et al., 2014; Wang et al., 2017; Peng et al., 2020). In addition, the increased adipogenesis of bone mesenchymal stem cells is another important cause of osteoporosis. With increasing age and changes in hormone secretion after menopause, bone marrow stromal cells (BMSCs) are more inclined toward adipogenic differentiation, and the risk of osteoporosis increases (Li et al., 2018; Zhang et al., 2021). This process is regulated in a variety of ways. The leptin receptor is a nutrient/fat receptor that acts on bone marrow mesenchymal cells to inhibit osteogenesis and promote adipogenesis. Osteocytes inhibit osteogenesis and promote adipogenesis by secreting neuropeptide Y. IL-11 also controls osteogenesis and systemic obesity under conditions of mechanical loading in the bone (Yue et al., 2016; Dong et al., 2022). This indicates that the mutual balance between osteogenesis and adipogenesis is a key indicator of bone homeostasis. In this study, we demonstrated that arginine significantly improved bone mass in aged and OVX mice, promoting the formation of type H vessels and reducing the production of adipocytes in bones. These results suggest that arginine has a positive effect on osteogenesis.

Mitophagy comprises an important regulatory mechanism for the intracellular removal of damaged mitochondria, ensuring the number of functional mitochondria. In the classical mitophagic pathway, damaged mitochondria cause the accumulation of PINK1 and Parkin, promoting the separation for autophagic degradation. Previous studies have shown that mitophagy works in the progression of neurodegenerative diseases (Mizushima and Levine, 2020; Pickles et al., 2018; Ashrafi and Schwarz,
In recent years, mitophagy in bone tissues has emerged as an important research topic. Mitophagy is involved in the regulation of osteoporosis, degenerative arthritis, and other bone diseases. The attenuation of mitophagy under oxidative stress can accumulate ROS in damaged mitochondria, which further promotes the differentiation and maturation of osteoclasts mediated by inflammatory factors (Sun et al., 2021; Wang et al., 2020; Deng et al., 2021; Sun et al., 2020). During the osteogenic differentiation of osteoblasts, mitochondrial biogenesis, function, and ATP content significantly increase. Damaged mitochondria release ROS and apoptotic factors, leading to the death or apoptosis of osteoblasts; however, they can be degraded by mitophagy to protect osteoblasts (Wang et al., 2020; Li et al., 2021). Interestingly, increased ROS levels and mitochondrial dysfunction were also observed during BMSC senescence, whereas increased autophagy could delay the process (Liu et al., 2021; Li et al., 2023; Guo et al., 2021). In this study, we demonstrated the positive effects of arginine on mitophagy in multiple cell types. By promoting the expression of Bnip3, arginine can protect cells against ROS. Recent studies have proven that the Bnip3 pathway regulates mitophagy during hypoxia (Madhu et al., 2020). These results suggest that mitophagy plays a pivotal role in bone homeostasis in osteoblasts, osteoclasts, and BMSCs. Notably, we found that the regulation of mitophagy-related proteins by arginine was inhibited by arginase II. The occurrence of osteoporosis is associated with an elevated level of oxidative stress, but the catabolism of arginine via the NO pathway is inhibited under oxidative stress (Geng et al., 2019; Ma et al., 2018). This finding suggested that the effect of arginine on mitophagy might be specifically related to its metabolic pathway in the cell and implied that arginase II might participate in regulating arginine-mediated mitophagy. We will further explore this possibility in subsequent studies.

In conclusion, arginine was found to delay osteoporosis in aged mice. In vitro experiments demonstrated that arginine could promote PINK1/Parkin- and Bnip3-mediated mitophagy, promote osteogenesis and angiogenesis, and inhibit adipogenesis. Furthermore, arginine may protect against bone formation in the presence of ROS. It was demonstrated that arginine could maintain bone homeostasis (Figure 8). The efficacy of arginine in preventing osteoporosis was further demonstrated in an OVX mouse model. Therefore, our work provides more insight into the relationship among arginine, mitophagy, and bone remodeling and suggests that arginine has the potential to be used as an adjuvant nutrient for the treatment of osteoporosis.

Abbreviations

ALP, alkaline phosphatase; ARS, alizarin red staining; BNIP3, BCL2 and adenovirus E1B 19kDa-interacting protein3; BV/TV, trabecular bone volume per total volume; cDNA, complementary DNA; DMEM, Dulbecco’s modified Eagle medium; FBS, fetal bovine serum; HUVEC, human umbilical vein endothelial cell; NIH, National Institute of Health; MAR, mineral apposition rate; OVX, ovariectomized; NO, nitric oxide; PBS, phosphate-buffered saline; PINK1, PTEN-induced kinase 1; PTH, parathyroid hormone; Tb.N, mean trabecular number; Tb.Sp, mean trabecular separation; Tb.Th, mean trabecular thickness

Declarations
Acknowledgments: This work was supported by the National Natural Science Foundation of China (grant number 82102591); Natural Science Foundation of Zhejiang Province (grant number LQ22H060001); Natural Science Foundation of Zhejiang Province (grant number Z20H060003); Zhejiang Medical and Health Science and Technology Program (grant number 2016KYB326); and Union Fund Project of National Natural Science Foundation of China (grant number U21A20351).

Author Contributions

Y.S., H.W., and H.X. performed the experiments and collected the data; all authors performed the data analysis and prepared the figures; Y.S., H.W., and H.X. wrote the manuscript; Z.X. W.X., and S.F. designed, supervised the overall study, and revised the manuscript.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Competing Interests

All authors state that they have no conflicts of interest.

References


Page 14/25


**Figures**
Arginine prevents bone loss in aged mice. (A) Representative micro-CT images of proximal femurs from vehicle group and arginine group. (B) Quantitative analyses of BV/TV, Tb.N, Tb.Sp, Tb.Th, Cor.Th and BMD (n=5 per group). (C) Representative images of Masson staining of decalcified bone sections from 2 groups. Scale bar=300μm. (D) Representative images of H.E., Von Kossa, OCN and perilipin staining of femurs from 2 groups. Scale bar=200μm. (E) Quantitative analyses of OCN and Perilipin positive cells in femora (n=5 per group). (F) Representative images of Calcein double fluorescent labeling in mouse femurs. Scale bar=5μm. (G) Quantitative analyses of MAR and BFR/BS (n=5 per group). (H) Immunostaining of CD31(green) and EMCN (red) in femurs. Scale bar=50μm.
Figure 2

Arginine promotes angio-osteogenesis but inhibits lipogenesis in vitro. (A) ALP and ARS staining of osteoblasts by different concentrations of arginine (n=3). (B) Western blot of osteoblasts by different concentrations of arginine. (C) Quantification of the ratio of band intensity of ALPL, OPN and RUNX2 relative to ACTIN of osteoblasts (n=3). (D) mRNA expression of Runx2, Ocn and Sp7 relative to Actin of osteoblasts (n=3). (E) Oil red O staining of C3h10 cells by different concentrations of arginine. Scale bar=200μm (n=3). (F) Western blot of C3h10 cells by different concentrations of arginine. (G) Quantification of the ratio of band intensity of PPARγ and FABP4 relative to ACTIN of C3h10 cells (n=3). (H) mRNA expression of Pparγ, Fabp4 and Klf5 relative to Actin of C3h10 cells (n=3).
**Figure 3**

Arginine promotes angiogenesis in a concentration-dependent manner in vitro. (A) Tube-forming results of HUVECs by different concentrations of arginine. Scale bar=200μm. (B) Quantitative analyses of Nb.nodes and Nb.junctons of tube forming results(n=3). (C) Wound healing experiments of HUVECs for 6h by different concentrations of arginine. Scale bar=200μm. (D) Quantitative analyses of wound healing percentage of wound healing results(n=3). (E) Transwell results of HUVECs by different concentrations of arginine. Scale bar=200μm. (F) Quantitative analyses of transwell cell number of transwell results(n=3).
Arginine rescues endothelial cells from ROS by affecting mitophagy. (A) Immunofluorescence of Mitotracker (red)-LC3 (green)-DAPI (blue) of HUVECs. Cells were treated with H$_2$O$_2$ (200μM) or arginine (200μM) for 24h. Scale bar=10μm. (B) mRNA expression of Pink1, Parkin and Bnip3 relative to Actin of HUVECs(n=3). (C) Western blot of HUVECs. (D) Quantification of the ratio of band intensity of PINK1, PARKIN, BNIP3 and LC3 relative to ACTIN of HUVECs (n=3). (E) Flow cytometry of HUVECs with JC-1. HUVECs were treated with H$_2$O$_2$ or arginine for 24h. (F) Quantitative analyses of fluorescence ratio of flow cytometry results. (G) Transmission electron microscope of HUVECs treated by H$_2$O$_2$ or arginine for 24h. Scale bar=0.2μm(n=3).
Figure 5

Arginine rescues osteoblasts from ROS by affecting mitophagy. (A) ALP and ARS staining of osteoblasts treated by H$_2$O$_2$ (200μM) or arginine (200μM) for 24h. (B) Quantitative analyses of integrated option density of ALP(left) and ARS(right) (n=3). (C) Flow cytometry of osteoblasts with JC-1. Osteoblasts were treated with H$_2$O$_2$ or arginine for 24h. (D) Quantitative analyses of fluorescence ratio of flow cytometry results. (E) Immunofluorescence of Mitotracker(red)-LC3(green)-DAPI(blue) of osteoblasts. Cells were treated with H$_2$O$_2$ (200μM) or arginine (200μM) for 24h. Scale bar=10μm. (F) Western blot of osteoblasts treated with H$_2$O$_2$ or arginine for 24h(up) or 1week(down). BNIP3 protein was detected in early stage, RUNX2 and OPN proteins were detected in late stage. (G) Quantification of the ratio of band intensity of BNIP3, OPN and RUNX2 relative to ACTIN of osteoblasts(n=3). (H) Transmission electron microscope of osteoblasts treated by H$_2$O$_2$ or arginine for 24h. Scale bar=0.2μm(n=3).
Figure 6

Arginine rescues C3h10 cells from ROS by affecting mitophagy. (A) Oil red O staining of C3h10 cells treated by H$_2$O$_2$ or arginine for 24h. Scale bar=200μm. (B) Flow cytometry of C3h10 cells with JC-1. C3h10 cells were treated with H$_2$O$_2$ (200μM) or arginine (200μM) for 24h. (C) Quantitative analyses of fluorescence ratio of flow cytometry results. (D) Immunofluorescence of Mitotracker(red)-LC3(green)-DAPI(blue) of C3h10 cells. Cells were treated with H$_2$O$_2$ or arginine for 24h. Scale bar=10μm. (E) Western blot of C3h10 cells treated with H$_2$O$_2$ (200μM) or arginine (200μM) for 24h. BNIP3, and adipogenic associated proteins CEBPa, FABP4, PPARγ were detected. (F) Quantification of the ratio of band intensity of BNIP3, CEBPa, FABP4 and PPARγrelative to ACTIN of osteoblasts(n=3). (G) Transmission electron microscope of C3h10 cells treated by H$_2$O$_2$ or arginine for 24h. Scale bar=0.2μm(n=3).
Figure 7

Arginine attenuates bone loss in OVX mice by promoting angio-osteogenesis. (A) Representative micro-CT images of proximal femurs from sham group, vehicle group, PTH group and arginine group. (B) Quantitative analyses of BV/TV, Tb.N, Tb.Sp and Tb.Th (n=5 per group). (C) Quantitative analyses of Cor.Th (n=5 per group). (D) Representative images of Calcein double fluorescent labeling in mouse femurs of 4 groups. Scale bar=5μm. (E) Quantitative analyses of MAR and BFR/BS (n=5 per group). (F) Representative images of H.E., Von Kossa and Masson staining of femurs from 4 groups. Scale bar=300μm (Masson) or 200μm (H.E. and Von Kossa).
Arginine attenuates bone loss in OVX mice by promoting angio-osteogenesis. (A) Representative immunofluorescence images of OCN staining of decalcified bone sections from 4 groups. Scale bar=200μm. (B) Quantitative analyses of Mean gray value of OCN Immunostaining (n=3 per group). (C) Representative immunofluorescence images of perilipin staining of decalcified bone sections from 4 groups. Scale bar=200μm. (D) Quantitative analyses of OCN and Perilipin positive cells in femora (n=5
Figure 9

**A schematic of proposed mechanism of arginine maintaining bone homeostasis. (A)** There are many types of cells in bone tissue. The addition of arginine can trigger the activity of endothelial cells, osteoblasts, mesenchymal stem cells, etc., promote osteogenic differentiation, inhibit adipogenic differentiation and promote angiogenesis. **(B)** After entering cells, arginine promotes the expression of mitochondrial proteins PINK1, PARKIN and BNIP3, and promotes the occurrence of mitophagy. Meanwhile, arginine could inhibit the decrease of Bnip3 expression in ROS state, and initiate mitophagy clearance of damaged mitochondria to protect cells. Notably, there are two pathways of arginine decomposition in the cells, by NOS and by arginase. The pathway of arginase II decomposition in mitochondria might be involved in the regulation of arginine on mitophagy.
This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarymaterials.docx